323578-34-3

Basic information

• Product Name: [1-(4-NITRO-BENZYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER
• Synonyms: [1-(4-NITRO-BENZYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER;tert-Butyl 1-(4-nitrobenzyl)piperidin-4-ylcarbamate
• CAS NO: 323578-34-3
• Molecular Formula: C₁₇H₂₅N₃O₄
• Molecular Weight: 335.4
• Mol File: 323578-34-3.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [1-(4-NITRO-BENZYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: [1-(4-NITRO-BENZYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER(323578-34-3)
• EPA Substance Registry System: [1-(4-NITRO-BENZYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER(323578-34-3)

Safety Data

• Hazardous Substances Data: 323578-34-3(Hazardous Substances Data)

Usage

General Description

The chemical [1-(4-nitro-benzyl)-piperidin-4-yl]-carbamic acid tert-butyl ester is a compound with the molecular formula C16H23N3O4. It is a tert-butyl ester of carbamic acid and contains a piperidine ring with a benzyl substituent. The nitro group attached to the benzyl group makes it a nitro compound. This chemical may have potential applications in pharmaceuticals or organic synthesis due to its structural features and functional groups. However, it is important to handle this compound with caution and follow safety protocols when working with it due to its potential hazards and toxicity.

Upstream product

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 50541-93-0 4-amino-1-benzylpiperidine 
• 73889-19-7 tert-butyl (1-benzylpiperidin-4-yl)carbamate 
• 100-14-1 4-nitrobenzyl chloride 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 92539-18-9 4-piperidinqmine, 1-<(4-nitrophenyl)methyl>- 
• 1637586-31-2 C₁₂H₁₇N₃O₂*C₂HF₃O₂ 
• 1637586-44-7 4-chloro-N-(1-(4-(3-ethylureido)benzyl)piperidin-4-yl)-2-methoxybenzamide 
• 1637586-86-7 C₁₈H₂₀N₄O₃ 
• 1637586-85-6 C₂₀H₂₁F₂N₃O₄ 
• 1637586-83-4 C₂₀H₁₉F₂N₃O₅ 
• 1637586-43-6 N-(1-(4-(3-ethylureido)benzyl)piperidin-4-yl)-5-methylpyrazine-2-carboxamide 
• 1637586-35-6 C₂₀H₂₂ClN₃O₄ 
• 1637586-34-5 C₁₈H₂₁N₅O₃ 
• 1637586-33-4 C₂₀H₁₉F₄N₃O₃ 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel 4-aminopiperidinyl-linked 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs

Based on the hybridization of the privileged fragments in DABO and DAPY-typed HIV-1 NNRTIs, a novel series of 4-aminopiperidinyl-linked 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives were designed, synthesized, and evaluated for their in vitro

Substituted 2-thioxothiazolidin-4-one derivatives showed protective effects against diabetic cataract via inhibition of aldose reductase

In an effort to develop a new class of potent aldose reductase inhibitors against diabetic cataracts, a series of novel 2-thioxothiazolidine-4-one derivatives was synthesized in excellent yields via a facile synthetic route. These compounds were tested against aldehyde (ALR1) and aldose reductase (ALR2) enzymes, where they showed considerable inhibitory activity. Among the tested derivatives, compound 6e showed selective and excellent inhibition of ALR2 over ALR1. The experimental diabetes was induced by the intraperitoneal administration of streptozotocin in male Wistar rats. Compound 6e showed positive modulation of body weight, blood glucose, and blood insulin levels in diabetic rats. Compound 6e also showed ALR2 inhibition as evidenced by Western blot analysis in lens homogenates of Wistar rats having cataract. The docking study of 6e was also performed inside the active site of ALR2 to enumerate the key contacts for inhibitory activity.

PYRAZOLO-QUINAZOLINE DERIVATIVES AS CHOLINE KINASE INHIBITORS

The present invention relates to substituted pyrazolo-quinazoline derivatives which modulate the activity of Choline Kinase (ChoK). The compounds of this invention are therefore useful in treating diseases caused by an altered choline metabolism, such as cancer, cell proliferative disorders, infectious diseases of different origin, immune- related disorders and neurodegenerative disorders. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.